ABVC BioPharma, Inc. (ABVC)
NASDAQ: ABVC · Real-Time Price · USD
2.979
+0.009 (0.31%)
Aug 14, 2025, 11:43 AM - Market open

Company Description

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.

The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.

It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer.

ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation.

The company is headquartered in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

ABVC BioPharma, Inc.
ABVC BioPharma logo
CountryUnited States
Founded2015
IndustryBiotechnology
SectorHealthcare
Employees19
CEOUttam Patil

Contact Details

Address:
44370 Old Warm Springs Boulevard
Fremont, California 94538
United States
Phone510 668 0881
Websiteabvcpharma.com

Stock Details

Ticker SymbolABVC
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001173313
CUSIP Number00091F106
ISIN NumberUS00091F3047
Employer ID26-0014658
SIC Code2834

Key Executives

NamePosition
Dr. Uttam Yashwant Patil Ph.D.Chief Executive Officer and Interim Chief Financial Officer
Eugene JiangChairman and Chief Business Officer
Dr. Tsung-Shann Jiang EMBA, Ph.D.Chief Scientific Officer, Chief Strategy Officer and Director

Latest SEC Filings

DateTypeTitle
Aug 14, 20258-KCurrent Report
Aug 13, 2025SCHEDULE 13G/AFiling
Aug 13, 202510-QQuarterly Report
Jul 18, 20258-K/A[Amend] Current report
Jul 15, 2025SCHEDULE 13D/AFiling
Jun 27, 2025S-8Securities to be offered to employees in employee benefit plans
Jun 4, 20258-KCurrent Report
Jun 3, 2025SCHEDULE 13DFiling
May 30, 20258-K/A[Amend] Current report
May 27, 2025POS AMPost-Effective amendments for registration statement